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Abstract 
According to 2014 National Survey on Drug Use and Health, 5.3% of pregnant women smoked 
marijuana in the past month. This prevalence is expected to increase as a growing number of states 
and countries are now considering legalization. Although umbilical cord is becoming a useful 
objective tool to detect in utero drug exposure, currently data about analytical methods and its 
utility to detect cannabis exposure are scarce. The objective of this work was to develop a method 
for the determination of 9-tetrahydrocannabinol (THC), 11-hydroxyTHC (THC-OH), 11-nor-9-
carboxy-THC (THCCOOH), 8--11-dihydroxyTHC (THC-diOH), THC and THCCOOH 
glucuronides, and cannabidiol (CBD) in umbilical cord by liquid chromatography-tandem mass 
spectrometry (LC-MS-MS) with dual ionization source. Umbilical cord samples (0.5g) were 
homogenized in methanol and extracted by solid phase extraction. Reversed-phase 
chromatographic separation was performed in 14 min, and two transitions per analyte were 
monitored in multiple reaction monitoring mode. Method validation included linearity (1-10 to 20-
200ng/g), precision (4.1-23.4%), accuracy (87.5-111.4%), matrix effect (-54.8 to -5.8%), 
extraction efficiency (25-45.6%), limits of detection and quantification (1-10ng/g), and 
endogenous (n=5) or exogenous interferences (not detected). The method was applied to 13 
authentic samples from cannabis-exposed newborns, which meconium samples had tested positive 
for cannabis. Twelve cord specimens tested positive for THCCOOH-Glucuronide (1.6-19.1ng/g). 
We developed and validated a specific and sensitive method for the simultaneous determination 
of THC, its metabolites, including THC and THCCOOH glucuronides, and CBD in umbilical cord 
samples by LC-MS/MS. The analysis of authentic samples showed the usefulness of umbilical 
cord to detect cannabis in utero exposure. 
 
Keywords: umbilical cord, cannabis, THC, pregnancy, LC-MS/MS 
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1. Introduction 
Cannabis is the one of the oldest and most widely used illicit drugs in the world. Due to 
the current increasingly permissive attitudes towards cannabis use and its legalization, the 
prevalence of cannabis has increased in recent years in the USA. According to National Survey on 
Drug Use and Health1, 12.5 % of the population aged 12 or older reported past-year cannabis use 
in 2014. This prevalence was higher among men (16.92%) than women (10.11%), but both genders 
showed an increase (+4% men, +2.66% women) from 2002 to 2014 2. Focusing in the women 
group, prevalence for pregnant women past-year cannabis users also increased from 8.6 % in 2002 
to 11.63% in 2014 3.  
Although the number of pregnant women using cannabis is rising, the adverse effects of 
fetal cannabis exposure are still less studied than the effects due to other illicit drugs 4. Fetal 
cannabis exposure may produce impaired neurodevelopment, low birth weight, preterm labor, and 
more requirement to place the newborn in the intensive care unit 4–8. However, there are no studies 
available that rigorously evaluate the impact of cannabis exposure on the developing fetus. The 
critical limitation in prior efforts has been inaccuracy of exposure assessment. 
Self-report is the most economic and common method to monitor drug exposure during 
pregnancy, but maternal interview may be unreliable due to underreporting issues 9. Analytical 
methods for the determination of drugs and metabolites in maternal and neonatal biological 
samples offer a more objective and reliable approach 10–12. Neonatal specimens (meconium, hair 
and urine) directly reflect fetal exposure to drugs during pregnancy. Among these specimens, 
meconium is the most common one employed to detect fetal drug exposure during the 3rd trimester 
12. The main disadvantage of meconium is its collection; it may be delayed up to 5 days after birth, 
and if it passes before birth, drug testing cannot be performed. 
Due to these reasons, umbilical cord has been suggested as an alternative specimen to 
detect in utero drug exposure. Umbilical cord is abundant, its collection is non-invasive and easy 
because it is considered as waste product 10,12. Although its window of detection is still not 
established, several studies showed agreement between meconium and umbilical cord results, 
indicating a similar window of detection 13–15. The current data available for cannabis in umbilical 
cord are scarce 14–16, and there is no information about the metabolite profile of THC in this 
biological samples, as well as at what concentrations these biomarkers are present. 
Cannabis and metabolites have been determined in meconium 17–20, but umbilical cord 
methods are limited 21,22. Chittama et al 21 developed a method for the determination of free 
THCCOOH in umbilical cord by immunoassay ELISA and liquid chromatography-time of flight 
mass spectrometry (LC-TOF). Montgomery et al 22 analyzed cannabinoids in umbilical cord by 
gas chromatography-mass spectrometry (GC-MS), but the authors did not indicate which 
cannabinoids were investigated, and no validation data were reported.  
The aim of the present study was to develop and validate a sensitive and specific method 
for the simultaneous determination of delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD) 
and five THC metabolites, 11-nor-9-carboxy-THC (THCCOOH), 11-hydroxy-THC (THC-OH), 
8-β-11-dihydroxy-THC (THC-diOH), THCCOOH-glucuronide and THC-glucuronide, in 
umbilical cord by liquid chromatography tandem mass spectrometry (LC-MS/MS). The method 
was applied for the analysis of the authentic umbilical cord samples from newborns exposed to 
cannabis during pregnancy.  
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2. Materials and Methods 
2.1. Chemicals and reagents 
THC, THC-OH, THC-COOH and CBD at 1 mg/mL, and THCCOOH-glucuronide and the 
internal standards (IStd) THC-d3, THC-OH-d3 and THCCOOH-d3 at 0.1 mg/mL in methanol were 
purchased from Cerilliant (Round Rock, TX, USA). THC-diOH and THC-diOH-d6 at 0.1 mg/mL 
and THC-glucuronide at 0.01 mg/mL in methanol were from ElSohly Laboratories (Oxford, MS, 
USA). Solid phase extraction (SPE) mixed-mode cation exchange cartridges (Strata Drug X-C, 3 
mL, 60 mg) were purchased from Phenomenex (Torrance, CA, USA). Formic acid was obtained 
from Pharmco-Aaper (Shelbyville, KY, USA). Methanol, acetonitrile, dichloromethane, and 
isopropanol were acquired from Fisher Scientific (Pittsburgh, PA, USA). Solvents for the 
extraction were high performance liquid chromatography (HPLC) grade and for the 
chromatographic instrument were liquid chromatography-mass spectrometry (LC-MS) grade. 
2.2. Umbilical cord and meconium samples 
Human blank umbilical cord samples were purchased from Lee BioSolutions (Maryland 
Heights, MO, USA), and were stored at -20 °C. Authentic samples were collected during a study, 
which aim was to investigate alternative matrices to detect in utero drug exposure 13. Umbilical 
cord samples were collected at delivery in polypropylene containers and stored at -20 °C until 
analysis, and meconium samples were collected from newborn diapers up to 3 days after delivery 
in polypropylene containers and also stored at -20 °C until analysis. The participants were pregnant 
women who delivered at the University Hospitals of Santiago de Compostela and Vigo, Spain, 
from January 2012 to December 2015. The participants were informed about the study both in 
writing and orally before the delivery, and they gave written consent. The subjects were not paid 
for their participation. The study was approved by the Ethics Committee of the University of 
Santiago de Compostela, Spain. 
2.3. Preparation of calibration and quality control umbilical cord samples 
A working solution at 1 g/mL containing all analytes except THC-glucuronide was 
prepared by dilution in methanol. Working solutions containing all analytes at 0.1 g/mL and 0.01 
g/mL were prepared by dilution in methanol. Internal standard mixture at 0.1 g/mL was 
prepared in methanol. All solutions were stored in amber vials at -20°C. Calibrators at 1, 2, 7, 10, 
20, 50, 100 and 200 ng/g were prepared by the addition of proper volumes of 0.01, 0.1 or 1 g/mL 
working solutions to 0.5 g blank umbilical cord samples. Low and high QC samples were prepared 
at 5 and 15 ng/g for THC-glucuronide, and at 15 and 150 ng/g for the other analytes.  
2.4. Umbilical cord sample preparation 
The umbilical cord sample was rinsed with ultra-pure water to remove maternal blood and 
biofluids. A segment of umbilical cord (0.5±0.02 g) was weighted and cut in small pieces. Three 
mL of methanol were added, and the samples were homogenized for 5 min using a tissue 
homogenizer (OMNI International, GA, USA) at speed 5.5. After centrifugation at 4960 rcf at 4°C 
for 15 min, the supernatants were transferred to new test tubes and evaporated at 55°C in a 
TurboVap LV evaporator (Biotage, Charlotte, NC, USA). The dried samples were reconstituted in 
3 mL of a mixture of 0.1% formic acid in water and in acetonitrile (70:30, v/v), vortexed and 
centrifuged at 4960 rcf at 4°C for 5 min. The samples were loaded onto Strata X-C cartridges that 
were conditioned with 3 mL methanol and 3 mL deionized water. After loading the sample, the 
cartridges were washed with 2 mL of 1% formic acid in water and 2 mL of a mixture of 1% formic 
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acid in water and methanol (70:30, v/v). The cartridges were dried under vacuum for 10 min. 
Elution was performed by 3 mL of a mixture of dichloromethane and isopropanol (30:70, v/v), and 
the eluates were evaporated at 45°C in a TurboVap LV evaporator. The dried samples were 
reconstituted with 200 L of a mixture of 0.1% formic acid in water and in acetonitrile (70:30, 
v/v), vortexed and transferred into screw top auto sampler vials. 
2.5. Umbilical cord method LC-MS/MS Instrumentation 
Ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-
MS/MS) instrument LCMS-8030 from Shimadzu (Columbia, MD, USA) was employed. The 
Nexera UHPLC system consisted of a binary LC-30AD pump, online degassing unit DGU-20A 
and cooled autosampler SIL-30AC. The triple quadrupole mass spectrometer with Dual Ionization 
Source (DUIS) was operated in the positive ionization mode with the following parameters: spray 
voltage, 4.5 kV; corona pin voltage, 4.5 kV; desolvation line temperature 250°C; heat block 
temperature 400°C; nebulizing gas flow rate 2 L/min and drying gas flow rate 15 L/min. Precursor 
to product ion transition optimizations were performed by injection of individual analytes at 0.01 
g/mL in methanol without column. Each compound was monitored by 2 transitions in MRM, 
multiple reaction monitoring mode (Table 1). Chromatographic separation was conducted on a 
Kinetex F5 column, 100 × 2.1 mm, 1.7 m (Phenomenex, Torrance, CA, USA) at 40°C. Mobile 
phase was 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B), at a flow rate 
of 0.5 mL/min, with the following gradient: initial composition of 30% B increased to 78.5% over 
8.5 min, then increased to 98% over 0.2 min, held for 3 min, and then returned to initial 
composition over 0.2 min and held for 2.1 min for a total run time of 14 min.  
2.6. Umbilical cord method validation 
The Scientific Working Group for Forensic Toxicology (SWGTOX) guidelines 23 were 
employed for method validation and the following parameters were evaluated: linearity, limit of 
detection (LOD), limit of quantification (LOQ), carryover, precision, accuracy, matrix effect (ion 
suppression or enhancement), extraction efficiency, process efficiency, interferences and 24h-auto 
sampler stability. 
Calibration model was evaluated with five different blank umbilical cord samples in five 
different days using five calibrator levels different from zero. Acceptable linearity was 
accomplished if the coefficient of determination (r2) was ≥ 0.95 and the residuals were < 20%. 
Limit of detection (LOD) and quantification (LOQ) were determined by fortifying five different 
umbilical cord samples at decreasing concentrations of compounds. Acceptance criteria for LOD 
involved signal-to noise > 3, retention time within ± 0.2 min from calibrators, and correct ion ratio 
qualifier to quantifier transition. LOQ met LOD criteria and had to quantify with acceptable 
precision (%CV < 20) and accuracy (80-120% of target concentration). Carryover was evaluated 
by injecting an extracted blank sample fortified with only IStd after an extracted sample fortified 
at 20 ng/g for THC-Glucuronide and 200 ng/g for other analytes (upper limit of quantification). 
Precision and accuracy were evaluated at low and high QC concentrations, 5 ng/g and 15 
ng/g for THC-Glucuronide, and 15 ng/g and 150 ng/g for others, in triplicate on five different 
days (n=15) using 5 different umbilical cord samples. Acceptable precision was achieved if the 
coefficient of variation (%CV) was less than 20%. Intra-assay precision was determined by the 
worst precision from the 5 different umbilical cord samples on 5 different days, and inter-assay 
precision considering all the replicates (n=15). Accuracy was represented as the percentage of 
the target concentration and was required to be within 80-120%.  
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For matrix effect, extraction efficiency and process efficiency evaluation, three sets of 
samples were prepared at low and high QC: blank samples fortified with analytes and IStd before 
(n=3) and after the extraction (n=6), and neat solutions (n=3). Matrix effect was evaluated by the 
comparison of the average peak area of samples fortified after extraction and neat solutions, 
(MeanAreaAfter/MeanAreaNeat - 1) x 100%. Process efficiency was calculated by comparing the 
average peak area of samples fortified before extraction and neat solutions, 
(MeanAreaBefore/MeanAreaNeat) x 100%. Extraction efficiency was calculated by the 
comparison of average peak areas in blank specimen fortified with analytes and IStd before and 
after extraction, (MeanAreaBefore/MeanAreaAfter) x 100%.   
Endogenous interferences were analyzed in five different blank umbilical cord specimens 
fortified with only IStd. Exogenous interferences were evaluated injecting neat solutions at 200 
ng/g of the following compounds: opiates (morphine, codeine, 6-monoacetylmorphine), 
amphetamines (amphetamine, methamphetamine, MDA, MDMA, MDEA), cocaine 
(benzoylecgonine, cocaine), methadone and benzodiazepines (alprazolam, clonazepam, 
flunitrazepam, diazepam). Autosampler stability was evaluated injecting low and high QCs stored 
at 10°C for 24 h in autosampler.  
 
2.7. Meconium samples analysis 
Meconium samples were analyzed by a previously published method 19. Briefly, 
0.25±0.02g meconium were homogenized in methanol and subjectred to cation exchange solid-
phase extraction. The extracts were analyzed by LC-MS/MS Quattro MicroTM API ESCI triple 
quadrupole (Waters Corp., Milford, MA, USA). Chromatographic separation was performed on a 
Kinetiex C18 column 50x2.1mm, 2.6 µm from Phenomenex at 35°C with a gradient of 0.1% 
formic acid in water and acetonitrile at a flow rate of 0.3 mL/min, with a total run time of 10 min. 
Two transitions per compound were monitored in MRM positive mode. The method was fully 
validated, the linearity ranged from 4 to 400 ng/g for all analytes, except for THC glucuronide (10-
400 ng/g). 
 
3. Results  
3.1.   Method validation 
The calibration model was linear, with 1/x2 weighting, non-forced through zero. The 
linearity range was from 1 to 20 ng/g for THC-Glucuronide, 1-200 ng/g for THCCOOH-
Glucuronide, 7-200 ng/g for THCCOOH, CBD and THC, and 10-200 ng/g for THC-diOH and 
THC-OH. The coefficients of determination (r2) of the calibration curves were ≥ 0.97 for all 
analytes, and residuals were less than 20%. The limits of detection and quantification ranged from 
1 to 10 ng/g. Table 2 shows the results for the linearity, LOD and LOQ for each compound. 
Precision and accuracy for each analyte were measured at low and high QC concentrations. Figure 
1 shows a umbilical cord sample fortified at the LOQ. Total precision ranged from 4.1 to 15.1%, 
intra-assay precision from 7.3 to 23.4%, and accuracy ranged from 87.5 to 111.4% (Table 3). 
Extraction and process efficiency ranged from 25 to 45.6%, and 11.6 to 42.2%, 
respectively. Matrix effect (ion suppression) was from -54.8 to -5.8% with its variation being ≤ 
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20% for all analytes, except for THC-glucuronide low QC (35.5%) and THCCOOH high QC 
(24.2%). Table 4 summarizes these results.  
No carryover was observed in a blank sample fortified with only IStd when it was injected 
after a sample fortified at 20 ng/g for THC-Glucuronide and 200 ng/g for other analytes. No 
quantifiable peaks were detected from five different blank umbilical cords at the retention time of 
each analyte. In addition, there were no exogenous interferences from opiates (morphine, codeine, 
6-monoacetylmorphine), amphetamines (amphetamine, methamphetamine, MDA, MDMA, 
MDEA), cocaine (benzoylecgonine, cocaine), methadone and benzodiazepines (alprazolam, 
clonazepam, flunitrazepam, diazepam). Autosampler stability was evaluated by reinjecting three 
low and high QCs stored at 10°C for 24 h in autosampler. No loss of any analyte was observed. 
3.2.   Authentic samples 
The present method was applied to thirteen authentic umbilical cord samples (sample ID 
1-13) from cannabis-exposed newborns, which meconium tested positive for THC and/or its 
metabolites, THC-OH, THC-diOH, THCCOOH, THC-glucuronide and/or THCCOOH-
glucuronide, and for CBD. Six mothers denied cannabis use during pregnancy (sample ID 1, 4, 5, 
8, 10 and 12), four admitted sporadic use (sample ID 3, 6, 9 and 11) and 2 daily use (sample ID 2 
and 13). Umbilical cord authentic samples were analyzed in 3 different batches. Each batch 
included a negative control (blank umbilical cord fortified with the IStd mixture only), calibrators, 
and low and high QCs.  
Twelve samples out of thirteen tested positive for cannabis in umbilical cord, showing a 
good agreement between umbilical cord and meconium (92.3% match). The predominant analytes 
in meconium samples were THCCOOH (n=12, 3.9 – 117.8 ng/g) and THC-diOH (n =11, 5.4 – 
887.4 ng/g). Four samples tested positive for THCCOOH-Glucuronide (19.4 – 190.2 ng/g), three 
samples for THC (3 – 15.6 ng/g) and two for THC-OH (3.7 – 164.2 ng/g). Nine samples were 
positive for CBD (9.8 – 335.3 ng/g). In the case of umbilical cord, THCCOOH-glucuronide was 
the only metabolite detected in the twelve samples at concentrations below 20 ng/g (1.6 -19.1 
ng/g). These results are shown in Figure 2 and Table 5. 
 
4. Discussion 
Meconium, neonatal hair and urine are commonly used for detection of in utero cannabis 
exposure. Due to the limitations of meconium, neonatal hair and urine, as difficulty of collection 
and sample availability, umbilical cord has been suggested as an alternative specimen 10,12. The 
present method was developed and validated for the simultaneous analysis of THC and its 
metabolites THC-OH, THC-diOH, THCCOOH, THC-glucuronide and THCCOOH-glucuronide, 
and CBD in umbilical cord samples using LC-MS/MS.  
Chittama et al. 21 developed a method for the screening of free THCCOOH in umbilical 
cord samples by ELISA and LC-TOF, and compared these methods’ performance against results 
obtained by GC-MS, analyzed by an outside laboratory (USDTL, Des Plaines, IL, USA). The 
ELISA and LC-TOF method required 1 g of umbilical cord, and the LOQ was 0.1 ng/g (ELISA) 
and 1 ng/g (LC-TOF). Although our method’s LOQ of THCOOH was higher (7 ng/g), the present 
method also confirms and quantifies THC, THC-OH, THC-diOH, THC-glucuronide, THCCOOH-
glucuronide and CBD, in 0.5 g of umbilical cord, achieving LOQs 1 – 10 ng/g. During the 
validation, all parameters were within the range of the established criteria 23, except matrix effect 
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variability (CV) for THC-glucuronide low QC (35.5%) and THCCOOH high QC (24.2%). The 
use of the appropriate internal standard compensated for these effects, and they did not 
compromise other parameters such as precision, accuracy, LOD and LOQ. With regard to the 
chromatographic separation, we evaluated different reversed-phase stationary phases, C18, 
phenyl-hexyl and pentafluorophenyl (F5) phases, with mobile phase 0.1% formic acid in water 
and acetonitrile. The main difference among the different columns was the glucuronides peak 
shape and resolution between CBD and THC. The best results were obtained with the F5 phase. 
Currently there are scarce data about the utility of umbilical cord to detect cannabis 
exposure during pregnancy 14,16,21, and there is no information about the predominant metabolites 
detected in this matrix. It is important to know this information because false negative results may 
occur from variations in the forms of THC metabolites present in a biological sample. Chittama et 
al. 21 reported free THCCOOH concentrations in umbilical cord by GC-MS from 0.06 to 6.09 ng/g 
(n=7). In twelve umbilical cord samples from newborns exposed to cannabis during pregnancy, 
we found only THCCOOH-Glucuronide at concentrations between 1.6 and 19.1 ng/g. We did not 
detect free THCCOOH, but our LOQ was 7 ng/g, higher than the concentrations previously 
reported for this metabolite (0.06 -6.09 ng/g) 21. Glucuronide metabolites have been reported as 
the predominant analytes in umbilical cord for other drugs, such as buprenorphine 24 and morphine 
13,25. Umbilical cord consists in three blood vessels surrounded by Wharton’s jelly. Wharton’s jelly 
is a gelatinous substance mainly made up of mucopolysaccharides, which are highly polar and 
attack water 26. This composition of the tissue may explain why polar metabolites such as 
glucuronides are accumulated in this matrix. In the present study, only one segment of the 
umbilical cord samples was analyzed, since homogeneous distribution of different types of 
analytes in this tissue were previously reported24,27.  
We analyzed thirteen umbilical cord samples from newborns, which meconium tested 
positive for THC, its metabolites, and/or CBD. Twelve out of thirteen were positive in umbilical 
cord, showing a 92.3% agreement; however, the metabolite profile was different in both matrices. 
In umbilical cord only THCCOOH-Glucuronide was detected, while in meconium free 
THCCOOH and THC-diOH were the predominant analytes, as previously reported 17,28,29. 
Montgomery et al. 15 reported a 90.7% agreement between meconium and umbilical cord for 
cannabinoids detection; however, no information about target analytes and concentrations were 
reported. Colby et al. 14 also found a good agreement between umbilical cord and meconium 
(76%). Out of 217 paired samples, 27 were positive in meconium and umbilical cord, 36 positive 
samples in meconium and negative in cord, 17 positive samples in cord and negative in meconium, 
and 137 negative samples in both matrices. In that study, only THCCOOH was analyzed in 
meconium (confirmation cut-off 5 ng/g) and in umbilical cord (screening cut-off 150 ng/g). 
Although the authors stated that the Chittama et al. 21 method was employed for the analysis of 
umbilical cord samples (cut-off of 0.1 ng/g in ELISA, 1 ng/g in LC-TOF), a surprisingly high 
THCCOOH cut-off in umbilical cord (150 ng/g) was reported. Palmer et al. 16 reported non-
difference between meconium and umbilical cord in overall detection of cannabis exposure during 
pregnancy. In this study, meconium and umbilical cord samples were not paired, and a comparison 
of the number of cases detected with these matrices was performed (7.7% in meconium, 9% in 
umbilical cord). Umbilical cord samples were screened by ELISA for free THCCOOH 21, but no 
confirmation was performed.    
A limitation of this study could be that only umbilical cord samples, which meconium 
tested positive to cannabis, were analyzed. Therefore, we did not evaluate if umbilical cord 
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samples could have tested positive and meconium negative. Based on the obtained results, this 
situation may be marginal, but further research should be performed. Another observation it is the 
higher concentrations observed in meconium compared to umbilical cord, and the different 
metabolite pattern in both biological samples. The different composition of the umbilical cord 
tissue and meconium, the physicochemical properties of the compounds, fetal metabolism, 
maternal dosing and timing may influence different accumulation in meconium and umbilical cord. 
The inclusion of additional metabolites, such as THC-OH glucuronide, which has been reported 
in meconium samples 17,28,29, may improve the umbilical cord detection. Currently, there are no 
data available about the clinical significance of these analytical results in umbilical cord samples. 
Gray et al. 30 compared neonatal growth outcomes in cannabis-exposed and non-exposed neonates, 
as determined by meconium analysis, and found reductions in gestational age, birth weight, head 
circumference, and length, yet most neonates were within the expected range for weight, head 
circumference, and length. More data are necessary to confirm THCCOOH-glucuronide as 
predominant metabolite in umbilical cord, to evaluate additional THC biomarkers in this biological 
sample, and to establish its window of detection and its clinical interpretation.   
 
5. Conclusion 
We developed and validated a specific and sensitive method for the determination of THC, 
its metabolites, including THC and THCCOOH glucuronides, and CBD in umbilical cord samples 
by LC-MS/MS. The analysis of authentic samples demonstrated the value of umbilical cord in 
detecting in utero cannabis exposure, and that THCCOOH-Glucuronide was the only THC 
metabolite detected in these samples.  
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Table 1. Liquid chromatography mass spectrometry parameters for delta-9-tetrahydrocannabinol 
(THC), cannabidiol (CBD) and five THC metabolites, 11-nor-9-carboxy-THC (THCCOOH), 11-
hydroxy-THC (THC-OH), 8-β-11-dihydroxy-THC (THC-diOH), THCCOOH-glucuronide and 
THC-glucuronide in umbilical cord. The quantifier transition is underlined. 
Analyte MRM 
Transition 
Collision 
energy(v) 
Ion ratio 
Qualifier/Quantifier 
(calibrators’ average) 
RT 
(min) 
IStd 
THC-diOH 347 > 311.2 
347 > 173 
-17 
-31 
0.2 3.1 THC-diOH-d6 
THC-diOH-d6 353.1 > 317.4 
353.1 > 178.9 
-16 
-25 
 3.2  
THCCOOH-
glucuronide 
521.1 > 345.1 
521.1 > 326.9 
-15 
-18 
0.2 3.4 THCCOOH-
glucuronide-d3 
THCCOOH-
glucuronide-d3 
524.1 > 348.2 
524.1 > 330.1 
-15 
-21 
 3.5  
THC-
glucuronide 
491.4 > 315.1 
491.4 > 192.9 
-17 
-39 
0.2 4 THCCOOH-
glucuronide-d3 
THC-OH 331.4 > 201.2 
331.4 > 133.1 
-27 
-25 
1 4.6 THC-OH-d3 
THC-OH-d3 334.1 > 196.1 
334.1 > 123 
-30 
-40 
 4.6  
THCCOOH 345 > 299.2 
345 > 193 
-21 
-28 
0.5 4.8 THCCOOH-d3 
THCCOOH-
d3 
348.1 > 330. 
348.1 > 302 
-17 
-23 
 4.8  
CBD 315.4 > 192.9 
315.4 > 135 
-23 
-20 
0.5 5.9 THC-d3 
THC 315.1 > 193.1 
315.1 > 122.9 
-23 
-38 
1.1 6.6 THC-d3 
THC-d3 318.1 > 195.9 
318.1 > 122.8 
-27 
-39 
 6.6  
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Table 2. Linearity parameters, linear range, and LOD/LOQ for delta-9-tetrahydrocannabinol 
(THC), cannabidiol (CBD) and five THC metabolites, 11-nor-9-carboxy-THC (THCCOOH), 11-
hydroxy-THC (THC-OH), 8-β-11-dihydroxy-THC (THC-diOH), THCCOOH-glucuronide) and 
THC-glucuronide in umbilical cord (n=5). 
Analyte LOD/LOQ 
(ng/g) 
Linearity 
Range  
(ng/g) 
Intercept±SD Slope±SD r2±SD 
THC-diOH 10 10-200 0.1018±0.080 0.55±0.05 0.975±0.009 
THCCOOH-
glucuronide 
1 1-200 0.1376±0.111 4.61±1.37 0.986±0.006 
THC-
glucuronide 
1 1-20 -0.1075±0.079 5.64±1.62 0.983±0.014 
THC-OH 10 10-200 -0.0237±0.110 0.35±0.08 0.979±0.003 
THCCOOH 7 7-200 0.0002±0.021 0.33±0.07 0.976±0.009 
CBD 7 7-200 0.2192±0.195 0.85±0.21 0.978±0.013 
THC 7 7-200 0.0593±0.108 0.82±0.07 0.979±0.007 
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Table 3. Precision and accuracy (n=15) for delta-9-tetrahydrocannabinol (THC), cannabidiol 
(CBD) and five THC metabolites, 11-nor-9-carboxy-THC (THCCOOH), 11-hydroxy-THC (THC-
OH), 8-β-11-dihydroxy-THC (THC-diOH), THCCOOH-glucuronide) and THC-glucuronide in 
umbilical cord at low and high QC (low QC at 5 ng/g and high QC at 15 ng/g for THC-
Glucuronide, and low QC at 15 ng/g and high QC at 150 ng/g for other compounds). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte Intra-day Precision 
(CV, %) 
Inter-day Precision 
(CV, %) 
Total Accuracy 
(%) 
Low QC High QC Low QC High QC Low QC High QC 
THC-diOH 11.1 7.3 9.3 4.1 107.4 111.4 
THCCOOH-
Glucuronide 
10.0 11.4 10.3 11.2 104.0 106.7 
THC-Glucuronide 10.5 16.2 9.5 12.4 103.1 104.5 
THC-OH 11.8 7.8 12.8 15.1 100.4 97.6 
THCCOOH 13.4 8.0 11.1 12.6 103.9 105.2 
CBD 17.2 17.6 14.5 14.3 87.5 97.4 
THC 23.4 7.9 12.5 4.6 100.4 108.2 
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Table 4. Matrix Effect (ion suppression or enhancement), Extraction Efficiency, and Process 
Efficiency for delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD) and five THC metabolites, 
11-nor-9-carboxy-THC (THCCOOH), 11-hydroxy-THC (THC-OH), 8-β-11-dihydroxy-THC 
(THC-diOH), THCCOOH-glucuronide) and THC-glucuronide in umbilical cord at low and high 
QC (low QC at 5 ng/g and high QC at 15 ng/g for THC-Glucuronide, and low QC at 15 ng/g and 
high QC at 150 ng/g for other compounds). 
Analyte Matrix Effect (CV, %) 
(n=6) 
Extraction Efficiency 
(n=3) 
Process Efficiency 
(n=3) 
Low QC High QC Low QC High QC Low QC High QC 
THC-diOH -44.2 
(6.1) 
-29.7 
(3.4) 
29.7 39.6 16.6 27.8 
THCCOOH-
glucuronide 
-21.4 
(7.7) 
-5.8 
(8) 
38.3 44.8 30.1 42.2 
THC-
glucuronide 
-43.5 
(35.5) 
-28.8 
(14.1) 
25.0 30.2 14.1 21.5 
THC-OH -54.8 
(7.7) 
-47.1 
(12.6) 
25.6 37.8 11.6 20.0 
THCCOOH -50.6 
(11.6) 
-44.4 
(24.2) 
28.1 39.5 13.9 22.0 
CBD -26.4 
(11.7) 
-33.2 
(7.1) 
31.2 36.0 22.9 24.0 
THC -41.6 
(20) 
-50.3 
(17.2) 
44.4 45.6 25.9 22.0 
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Table 5. Authentic matched meconium and umbilical cord samples from thirteen newborns 
exposed to cannabis during pregnancy. THC, delta-9-tetrahydrocanninol; CDB, cannabidiol; 
THC-COOH, 11-nor-9-carboxy-THC; THC-OH, 11-hydroxy-THC; THC-diOH, 8-β-11-
dihydroxy-THC; THCCOOH-glucuronide, 11-nor-9-carboxy-THC– glucuronide. ND, not 
detected. 
Sample ID 
Meconium  
(ng/g) 
Umbilical Cord 
(ng/g) 
THCCOOH THC-diOH 
THCCOOH-
glucuronide THC 
THC-
OH CBD 
THCCOOH-
Gluc 
1 3.9 21.4 ND ND 3.7 ND ND 
2 15.8 90 ND ND ND ND 12.3 
3 14.6 85 ND ND ND 9.5 1.6 
4 48.4 887.4 ND ND 164.2 ND 6.8 
5 9.3 18.1 19.4 ND ND 18.5 16.3 
6 23.4 ND ND ND ND 31.4 2.2 
7* 45 53.2 190.2 5.6 ND 112.1 19.1 
8 19.7 30.8 ND ND ND 56.5 4.3 
9 117.8 5.4  ND 15.6 ND 335.3 3.6 
10 6.2 88.2 ND 3 ND 30.8 3.2 
11 44.4 ND 67.4 ND ND 74.6 14.6 
12 8.4 47.6 111.8 ND ND 19.7 5.1 
13 ND 43.2 ND ND ND ND 2.8 
*Note: Sample ID 7 meconium results were previously reported in reference19, and it 
corresponds with sample 1910/2015. 
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Figure1. MRM chromatograms of the quantifier (black line) and qualifier (pink line) transitions 
in blank umbilical cord fortified at the limit of quantification, 1 ng/g for THCCOOH-
Glucuronide and THC-Glucuronide, 7 ng/g for THCCOOH, THC and CBD, and 10 ng/g for 
THC-OH and THC-diOH. 
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Figure 2. MRM chromatograms of the quantifier (black line) and qualifier (pink line) transitions 
in an authentic umbilical cord sample (sample ID 8) positive for THCCOOH-Glucuronide at 4.3 
ng/g.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
